Eubel Brady & Suttman Asset Management Inc. Increases Stake in Kenvue Inc. (NYSE:KVUE)

Eubel Brady & Suttman Asset Management Inc. boosted its stake in shares of Kenvue Inc. (NYSE:KVUE) by 0.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 961,138 shares of the company’s stock after purchasing an additional 4,086 shares during the period. Kenvue makes up about 2.7% of Eubel Brady & Suttman Asset Management Inc.’s portfolio, making the stock its 13th biggest position. Eubel Brady & Suttman Asset Management Inc. owned approximately 0.05% of Kenvue worth $20,520,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of KVUE. FMR LLC increased its holdings in shares of Kenvue by 2.3% in the third quarter. FMR LLC now owns 137,915,493 shares of the company’s stock valued at $3,189,985,000 after purchasing an additional 3,075,019 shares during the period. State Street Corp boosted its position in Kenvue by 16.8% in the third quarter. State Street Corp now owns 127,213,940 shares of the company’s stock valued at $2,942,458,000 after buying an additional 18,283,473 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Kenvue by 8.9% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 86,979,341 shares of the company’s stock worth $2,011,832,000 after buying an additional 7,115,374 shares during the period. Geode Capital Management LLC increased its holdings in Kenvue by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 44,677,077 shares of the company’s stock worth $1,029,810,000 after buying an additional 399,846 shares during the period. Finally, Harris Associates L P raised its position in Kenvue by 7.5% during the 3rd quarter. Harris Associates L P now owns 31,459,511 shares of the company’s stock worth $727,658,000 after buying an additional 2,186,114 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research reports. Citigroup cut their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. Canaccord Genuity Group cut their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upgraded Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $23.00.

Kenvue Trading Up 4.1 %

Shares of NYSE:KVUE opened at $23.31 on Friday. The business’s 50 day moving average price is $21.29 and its 200-day moving average price is $22.14. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The firm has a market capitalization of $44.68 billion, a price-to-earnings ratio of 43.97, a price-to-earnings-growth ratio of 2.61 and a beta of 1.45. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th will be paid a dividend of $0.205 per share. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.52%. Kenvue’s dividend payout ratio (DPR) is currently 154.72%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.